Similar Articles
1021 Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells
1022 Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients
1023 Biological features and biomarkers in hepatocellular carcinoma
1024 Optimal combination of antiangiogenic therapy for hepatocellular carcinoma
1025 Transcatheter arterial infusion for advanced hepatocellular carcinoma: Who are candidates?
1026 Current management of patients with hepatocellular carcinoma
1027 Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy
1028 Current and future treatments for hepatocellular carcinoma
1029 Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma
1030 Perspective of laparoscopic liver resection for hepatocellular carcinoma
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA